ICD-10-CM Coding for Malignant Neoplasm of Overlapping Sites of Right Breast, Female, Estrogen Receptor Positive
The correct ICD-10-CM code is C50.811 for malignant neoplasm of overlapping sites of right breast, female, combined with Z17.0 for estrogen receptor positive status.
Primary Diagnosis Code
The anatomic site code C50.811 specifically identifies:
- C50 = Malignant neoplasm of breast
- .8 = Overlapping sites of breast (lesion involving two or more contiguous sites)
- 11 = Right breast, female
This code captures the precise anatomic location when the tumor involves multiple overlapping areas of the right breast that cannot be classified to a single specific site (such as upper outer quadrant, lower inner quadrant, etc.).
Required Additional Code for Receptor Status
Z17.0 must be added as a secondary code to document estrogen receptor positive status. This is critical because:
- Receptor status directly impacts treatment decisions and prognosis
- It is required for accurate staging under the AJCC 8th edition TNM system, which incorporates biological markers 1
- Estrogen receptor positivity indicates eligibility for endocrine therapy, which reduces recurrence odds by 41% and death odds by 31% 2
Complete Coding Structure
Primary code: C50.811 (Malignant neoplasm of overlapping sites of right breast, female)
Secondary code: Z17.0 (Estrogen receptor positive status [ER+])
Clinical Context
The estrogen receptor positive designation is essential for treatment planning. For ER-positive breast cancers, endocrine therapy is the cornerstone of adjuvant treatment regardless of age, lymph node status, or whether chemotherapy is administered 2. The specific treatment approach varies based on menopausal status, with options including tamoxifen, aromatase inhibitors, and ovarian function suppression in premenopausal women 3.
Common Coding Pitfalls to Avoid
- Do not use C50.9 (unspecified site of breast) when overlapping sites are documented
- Do not omit the laterality digit (the final "1" indicating right breast)
- Do not forget Z17.0 - receptor status is not optional; it's a required component of complete cancer coding
- Do not use C54.x codes - these are for uterine/endometrial malignancies, not breast 4
The combination of these two codes provides complete documentation for billing, registry reporting, and clinical decision support systems.